News

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” says Dr. Joseph Rizzo, professor of ophthalmology at Harvard Medical School ...
The condition, called nonarteritic anterior ischemic optic neuropathy (NAION), affects around 2.3 people per 100,000 people in the United States.
NAION is a condition that causes sudden blindness, typically in one eye, due to a lack of blood flow to the optic nerve. There is no known treatment for the condition.
The matched cohort study from Rizzo's team used data from 16,827 neuro-ophthalmic patients at Massachusetts Eye and Ear from December 2017 to November 2023 who had no NAION diagnosis before ...
Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden ...
NAION is the second-leading cause of optic nerve blindness (second only to glaucoma) and it is the most common cause of sudden optic nerve blindness. NAION is thought to be caused by reduced blood ...
Those who take Ozempic or Wegovy may have an increased risk of developing a rare form of blindness, though future research is needed to make a final determination, researchers in a new study said.
NAION refers to a loss of blood flow to the optic nerve (the cable that connects the eye to the brain). This condition typically causes sudden vision loss in one eye without any pain.
NAION is the second most common optic nerve disease in the U.S., occurring in up to 10 out of 100,000 people, according to the American Academy of Ophthalmology, and it’s one of the most common ...
Of the nine people studied, seven had a type of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION). This occurs when there is insufficient blood flow to the optic nerve, ...
Parker Waichman LLP Files One of the First NAION Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County. PR Newswire. PORT WASHINGTON, N.Y., April 15, 2025.